YSXT:NASDAQYSX Tech. Co., Ltd Analysis
Data as of 2026-06-02 - not real-time
$1.04
Latest Price
8/10Risk
Risk Level: High
Executive Summary
YSX Tech (YSXT) trades at a **trailing P/E of 4.95**, dramatically below the industry average of 29.79, and a **price‑to‑book of 0.79**, suggesting a strong value case on paper. The company posted **20% revenue growth** to $78.3 M, yet margins remain thin (gross margin ~10%) and cash generation is weak, with **operating cash flow of –$13.5 M** and **free cash flow of –$14.8 M**. Recent announcements of two partnerships to accelerate digital transformation in China’s insurance sector could improve top‑line momentum, but the benefits are still uncertain.
Technical indicators show a **bearish trend** with price below the 50‑day SMA (1.15) and near the **support level of $0.93**, while the MACD has turned mildly bullish and the RSI sits at 44, indicating limited short‑term upside. Volatility is high at **55% over 30 days**, beta is negative (–0.25), and the stock has suffered an **88% max drawdown**, all pointing to substantial downside risk and liquidity constraints.
Technical indicators show a **bearish trend** with price below the 50‑day SMA (1.15) and near the **support level of $0.93**, while the MACD has turned mildly bullish and the RSI sits at 44, indicating limited short‑term upside. Volatility is high at **55% over 30 days**, beta is negative (–0.25), and the stock has suffered an **88% max drawdown**, all pointing to substantial downside risk and liquidity constraints.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 4/10
Key Factors
- Bearish price trend and proximity to support
- High volatility and decreasing volume
- Negative cash flow despite low valuation
Medium Term
1–3 yearsNeutral
Model confidence: 5/10
Key Factors
- Undervalued multiples versus peers
- Revenue growth of 20% but thin margins
- Uncertainty around cash‑flow turnaround
Long Term
> 3 yearsPositive
Model confidence: 6/10
Key Factors
- Strategic partnerships targeting digital services
- Significant valuation discount to industry
- Potential for improved profitability if cash‑flow issues are resolved
Key Metrics & Analysis
Financial Health
Revenue Growth20.20%
Profit Margin6.09%
P/E Ratio5.0
ROE18.36%
ROA8.42%
Debt/Equity24.46
P/B Ratio0.8
Op. Cash Flow$-13513699
Free Cash Flow$-14836077
Industry P/E29.8
Technical Analysis
TrendBearish
RSI44.8
Support$0.93
Resistance$1.22
MA 20$1.04
MA 50$1.15
MA 200$1.73
MACDBullish
VolumeDecreasing
Fear & Greed Index92.77
Valuation
GradeUndervalued
TypeValue
Risk Assessment
Beta-0.25
Volatility55.38%
Sector RiskMedium
Reg. RiskHigh
Geo RiskHigh
Currency RiskMedium
Liquidity RiskHigh
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.